Malin Corp PLC - Ireland-based investor in life sciences companies - Says intrinsic equity value per share EUR9.24 as at June 30, up 9% on December 31's EUR8.48. "This has decreased to EUR8.83 per share as at 25 August 2021, as a result of declines in the share prices of Immunocore and Poseida in the period," firm notes. Says first half was period of "strong achievement" as it noted the sale of Kymab and Altan at "significant" premiums. "As we look ahead to the remainder of 2021, we will seek to demonstrate further execution of our business strategy with the close of the Altan company sale, an expected return of capital to shareholders and further value accretion from our remaining assets," company says.
Current stock price: EUR6.85
Year-to-date change: up 67%
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
